Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 4Withdrawn 1Terminated 1

Sponsor Class

NIH 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 2Sarcoma 1Breast 1

Conditions

Uveal Melanoma 1Osteosarcoma 1Melanoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 1499Cisplatin 1434Paclitaxel 1339Radiotherapy 1310Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × CR011-vcMMAE × Clear all
NCT02487979 2022-01-18

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 15 charts
Sarcoma

Osteosarcoma

NCT02363283 2020-08-21

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT00412828 2015-02-19

A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma

Celldex Therapeutics

Phase 1/2 Completed
117 enrolled
Dermatologic

Melanoma

NCT00704158 2015-02-19

Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer

Celldex Therapeutics

Phase 1/2 Completed
42 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡